SEC Comment Letter 0000000000-24-010869 to FIRST MERCHANTS CORP (FRME)
FIRST MERCHANTS CORP
Date: Sept. 25, 2024 · CIK: 0000712534 · Accession: 0000000000-24-010869
AI Filing Summary & Sentiment
File numbers found in text: 001-41342
Show Raw Text
September 24, 2024
Michele M. Kawiecki
Chief Financial Officer
First Merchants Corporation
200 East Jackson Street
Muncie, Indiana 47305
Re:First Merchants Corporation
Form 10-K for the Fiscal Year Ended December 31, 2023
File No. 001-41342
Dear Michele M. Kawiecki:
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2023
Item 1C. Cybersecurity, page 30
1.We note your Chief Information Security Officer (CISO) is responsible for assessing and
managing risks from cybersecurity threats, and we note the Information Security
Committee (ISC) assists executive management and the Board of Directors in their
oversight of responsibilities related to information security. You also state that the ISC
reviews and recommends security-related policies and standards, among other activities
related to cyber risks. We also note that you describe the relevant expertise of your CISO
but not of the other members of the ISC. Please revise future filings to discuss the relevant
expertise of such members of senior management as required by Item 106(c)(2)(i) of
Regulation S-K.
September 24, 2024
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Irene Paik at 202-551-6553 or James Lopez at 202-551-3536 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences